Melosky, B., Bradbury, P., Tu, D., Florescu, M., Reiman, A., Nicholas, G., Basappa, N., Rothenstein, J., Goffin, J. R., Laurie, S. A., Wheatley-Price, P., Leighl, N., Goss, G., Reaume, M. N., Butts, C., Murray, N., Card, C., Ko, J., Blais, N., Gray, S., Lui, H., Brown-Walker, P., Kaurah, P., Prentice, L. M., & Seymour, L. (2019). selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. Lung cancer, 133, 48–55. http://access.bl.uk/ark:/81055/vdc_100085410484.0x00004f